Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2016, Article ID 3682936, 8 pages
http://dx.doi.org/10.1155/2016/3682936
Research Article

5-HT2A Receptor Binding in the Frontal Cortex of Parkinson’s Disease Patients and Alpha-Synuclein Overexpressing Mice: A Postmortem Study

1Research Laboratory for Stereology and Neuroscience, Bispebjerg and Frederiksberg Hospitals, Copenhagen University Hospital, 2300 Copenhagen, Denmark
2Department of Neuroscience and Pharmacology, University of Copenhagen, 2200 Copenhagen, Denmark
3Department of Drug Design and Pharmacology, University of Copenhagen, 2200 Copenhagen, Denmark
4Department of Neurodegeneration, Lundbeck A/S, Ottiliavej 9, 2500 Valby, Denmark
5Laboratory of Neuropsychiatry, Department of Neuroscience and Pharmacology, University of Copenhagen and Mental Health Center Copenhagen, 2200 Copenhagen, Denmark

Received 20 April 2016; Revised 24 June 2016; Accepted 5 July 2016

Academic Editor: Per Odin

Copyright © 2016 Nadja Bredo Rasmussen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. M. A. Antony, N. J. Diederich, R. Krüger, and R. Balling, “The hallmarks of Parkinson's disease,” FEBS Journal, vol. 280, no. 23, pp. 5981–5993, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. R. B. Postuma, D. Aarsland, P. Barone et al., “Identifying prodromal Parkinson's disease: pre-Motor disorders in Parkinson's disease,” Movement Disorders, vol. 27, no. 5, pp. 617–626, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Simuni and K. Sethi, “Nonmotor manifestations of Parkinson's disease,” Annals of Neurology, vol. 64, supplement 2, pp. S65–S80, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Aznar and M. E. Hervig, “The 5-HT2A serotonin receptor in executive function: implications for neuropsychiatric and neurodegenerative diseases,” Neuroscience & Biobehavioral Reviews, vol. 64, pp. 63–82, 2016. View at Publisher · View at Google Scholar
  5. S. Aznar and A. B. Klein, “Regulating prefrontal cortex activation: an emerging role for the 5-HT2A serotonin receptor in the modulation of emotion-based actions?” Molecular Neurobiology, vol. 48, no. 3, pp. 841–853, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. J. P. M. Van Der Vegt, O. J. Hulme, S. Zittel et al., “Attenuated neural response to gamble outcomes in drug-naive patients with Parkinson's disease,” Brain, vol. 136, no. 4, pp. 1192–1203, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Marner, V. G. Frokjaer, J. Kalbitzer et al., “Loss of serotonin 2A receptors exceeds loss of serotonergic projections in early Alzheimer's disease: a combined [11C]DASB and [18F]altanserin-PET study,” Neurobiology of Aging, vol. 33, no. 3, pp. 479–487, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Holm, A. Ettrup, A. B. Klein et al., “Plaque deposition dependent decrease in 5-HT2A serotonin receptor in aβPPswe/PS1dE9 amyloid overexpressing mice,” Journal of Alzheimer's Disease, vol. 20, no. 4, pp. 1201–1213, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Huot, S. H. Fox, and J. M. Brotchie, “The serotonergic system in Parkinson's disease,” Progress in Neurobiology, vol. 95, no. 2, pp. 163–212, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. A. J. Newman, D. Selkoe, and U. Dettmer, “A new method for quantitative immunoblotting of endogenous α-synuclein,” PLoS ONE, vol. 8, no. 11, Article ID e81314, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. B. R. Lee and T. Kamitani, “Improved immunodetection of endogenous α-synuclein,” PLoS ONE, vol. 6, no. 8, Article ID e23939, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. G. H. Petit, E. Berkovich, M. Hickery et al., “Rasagiline ameliorates olfactory deficits in an α-synuclein mouse model of Parkinson's disease,” PLoS ONE, vol. 8, no. 4, Article ID e60691, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Westerlund, C. Ran, A. Borgkvist et al., “Lrrk2 and α-synuclein are co-regulated in rodent striatum,” Molecular and Cellular Neuroscience, vol. 39, no. 4, pp. 586–591, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Paxinos and K. B. J. Franklin, The Mouse Brain in Stereotaxic Coordinates, Academic Press, 2nd edition, 2001.
  15. T. D. Schmittgen and K. J. Livak, “Analyzing real-time PCR data by the comparative CT method,” Nature Protocols, vol. 3, no. 6, pp. 1101–1108, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. C. P. L.-H. Chen, J. T. Alder, L. Bray, A. E. Kingsbury, P. T. Francis, and O. J. F. Foster, “Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex,” Annals of the New York Academy of Sciences, vol. 861, pp. 288–289, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Melse, S. K. Tan, Y. Temel, M. J. van Kroonenburgh, and A. F. Leentjens, “Changes in 5-HT2A receptor expression in untreated, de novo patients with Parkinson's disease,” Journal of Parkinson's Disease, vol. 4, no. 2, pp. 283–287, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Braak, K. Del Tredici, U. Rüb, R. A. I. De Vos, E. N. H. Jansen Steur, and E. Braak, “Staging of brain pathology related to sporadic Parkinson's disease,” Neurobiology of Aging, vol. 24, no. 2, pp. 197–211, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Braak, E. Ghebremedhin, U. Rüb, H. Bratzke, and K. Del Tredici, “Stages in the development of Parkinson's disease-related pathology,” Cell and Tissue Research, vol. 318, no. 1, pp. 121–134, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Sasaki, H. Gemba, A. Nambu, and R. Matsuzaki, “No-go activity in the frontal association cortex of human subjects,” Neuroscience Research, vol. 18, no. 3, pp. 249–252, 1993. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Chudasama and T. W. Robbins, “Functions of frontostriatal systems in cognition: comparative neuropsychopharmacological studies in rats, monkeys and humans,” Biological Psychology, vol. 73, no. 1, pp. 19–38, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Li, X.-F. Huang, C. Deng et al., “Alterations in 5-HT2A receptor binding in various brain regions among 6-hydroxydopamine-induced Parkinsonian rats,” Synapse, vol. 64, no. 3, pp. 224–230, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. I. Yasue, S. Matsunaga, T. Kishi, K. Fujita, and N. Iwata, “Serotonin 2A receptor inverse agonist as a treatment for Parkinson's disease psychosis: a systematic review and meta-analysis of serotonin 2A receptor negative modulators,” Journal of Alzheimer's Disease, vol. 50, no. 3, pp. 733–740, 2016. View at Publisher · View at Google Scholar · View at Scopus